



Rexahn Pharmaceuticals, Inc.
Investor Relations Department
15245 Shady Grove Road, Suite
455
Rockville, MD 20850
United States

Visit IR website [↗](#)
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	1.99
Trade Time:	12:39 PM ET 12/12/17
Change:	-0.05 ↓ (2.402%)
Day Range	1.96 - 2.08
52-Week Range	1.27 - 7.10
Volume	276,907

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 12/11/17**
[Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium](#)
- 11/09/17**
[Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference](#)
- 11/08/17**
[Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer](#)
- 11/06/17**
[Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- 10/13/17**
[Rexahn Announces \\$8 Million Registered Direct Offering](#)

Financials [\[View all \]](#)

- Third Quarter Financial Results**
- 02/24/17**
[Annual Report \(10-K\)](#)
- 02/24/17**
[Proxy Statement \(DEF 14A\)](#)
- 11/03/17**
[Quarterly Report \(10-Q\)](#)
- 08/04/17**
[Quarterly Report \(10-Q\)](#)
- 05/03/17**
[Quarterly Report \(10-Q\)](#)